ANGELA RENE JOHNSON

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family WINFIELD, KS NPI 1770129140

General Payments — all program years on this page

$1,055.09

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 64
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $323.93 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $323.9317

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $144.797
Novo Nordisk AS $64.783
Bayer HealthCare Pharmaceuticals Inc. $33.782
Lilly USA, LLC $31.322
Amgen Inc. $19.971
IDORSIA PHARMACEUTICALS US INC $16.121
ABBVIE INC. $13.171

By program year

Program yearAmountRecords
2021 $224.2114
2022 $322.7321
2023 $184.2212
2024 $323.9317

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086275864 Bayer Healthcare Pharmaceuticals Inc. $17.07 03/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086338709 Bayer Healthcare Pharmaceuticals Inc. $16.71 08/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100521487 Novo Nordisk Inc $18.24 04/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100572832 Novo Nordisk Inc $21.38 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100652517 Novo Nordisk Inc $25.16 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104424977 AstraZeneca Pharmaceuticals LP $14.10 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105310761 AstraZeneca Pharmaceuticals LP $23.53 04/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105374251 AstraZeneca Pharmaceuticals LP $17.70 02/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105398215 AstraZeneca Pharmaceuticals LP $15.04 05/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105495017 AstraZeneca Pharmaceuticals LP $17.36 04/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105532436 AstraZeneca Pharmaceuticals LP $21.89 12/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105813523 AstraZeneca Pharmaceuticals LP $35.17 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107407986 ABBVIE INC. $13.17 08/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115768479 Amgen Inc. $19.97 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135472887 Lilly USA, LLC $15.76 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135512616 Lilly USA, LLC $15.56 01/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146762571 IDORSIA PHARMACEUTICALS US INC $16.12 01/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.